Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
Apr 20, 2023	Definitive proxy statement relating to merger or acquisition	DEFM14A	Mergers & Acquisitions	0001104659-23-047840.pdf 0001104659-23-047840.rtf 0001104659-23-047840.xls View HTML
Aug 28, 2019	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001750019-19-000053.pdf 0001750019-19-000053.rtf 0001750019-19-000053.xls View HTML
Aug 14, 2020	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-20-220342.pdf 0001193125-20-220342.rtf 0001193125-20-220342.xls View HTML
Sep 03, 2021	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-21-265554.pdf 0001193125-21-265554.rtf 0001193125-21-265554.xls View HTML
Sep 01, 2022	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-22-236510.pdf 0001193125-22-236510.rtf 0001193125-22-236510.xls View HTML
May 22, 2023	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001104659-23-062928.pdf 0001104659-23-062928.rtf 0001104659-23-062928.xls View HTML
May 24, 2023	Additional proxy soliciting materials - definitive	DEFA14A	Proxy Filings	0001193125-23-153028.pdf 0001193125-23-153028.rtf 0001193125-23-153028.xls View HTML
Aug 28, 2019	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	Proxy Filings	0001750019-19-000051.pdf 0001750019-19-000051.rtf 0001750019-19-000051.xls View HTML
Aug 14, 2020	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	Proxy Filings	0001193125-20-220330.pdf 0001193125-20-220330.rtf 0001193125-20-220330.xls View HTML
Sep 03, 2021	Official notification to shareholders of matters to be brought to a vote ("Proxy")	DEF 14A	Proxy Filings	0000950170-21-001674.pdf 0000950170-21-001674.rtf 0000950170-21-001674.xls View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.